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Understanding how frailty affects health-related quality of life (HRQOL) in those with 
chronic kidney disease (CKD) could assist in the development of management strategies to 
improve outcomes for this vulnerable patient group. This study aimed to evaluate the 
relationship between frailty and HRQOL in patients with CKD stage 4 and 5 (G4-5) and those 
established on haemodialysis (G5D). 
 
Methods 
Ninety participants with CKD G4-5D were recruited between December 2016 and December 
2017. Frailty was assessed using the Frailty Phenotype, which included assessments of 
unintentional weight loss, weakness (handgrip strength), slowness (walking speed), physical 
activity and self-perceived exhaustion. HRQOL was assessed using the RAND 36-Item Health 
Survey Version 1.0 (SF-36).  
 
Results 
Nineteen (21%) patients were categorised as frail. Frailty, when adjusted for age, gender, 
dialysis-dependence and comorbidity, had a significant effect on five of the eight SF-36 
domains: physical functioning, role limitations due to emotional problems, energy/fatigue, 
social functioning and pain. Regression modelling best explained the variation in the 
physical functioning domain (adj. R2 = 0.27, p <0.001), with frailty leading to a 26-point 
lower score. Exhaustion was the only Frailty Phenotype component that had a significant 
effect on scores across all SF-36 domains. 
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Conclusions 
Frailty is independently associated with worse HRQOL in patients with CKD G4-5D, with self-
perceived exhaustion being the most significant Frailty Phenotype component contributing 
to HRQOL. Efforts should be made to identify frail patients with CKD so that management 
strategies can be offered that aim to improve morbidity, mortality and patient-reported 
outcomes, including HRQOL and fatigue. 
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INTRODUCTION 
 
Frailty is the result of a sustained deterioration in multiple physiological processes that leads 
to a state of increased vulnerability associated with disability, hospitalisations and an 
increased mortality risk [1]. The prevalence of frailty is markedly higher in those with 
chronic kidney disease (CKD) than in the general older population [2,3]. The trajectory from 
robustness to frailty is associated with progressive renal impairment, with significant muscle 
wasting, a major contributor to physical frailty in CKD patients, occurring prior to the 
commencement of dialysis [4-6]. Importantly, frailty is an independent risk factor for falls, 
hospitalisation and death in those with CKD [2,4,7-14]. 
 
Irrespective of frailty status, patients with CKD have a considerable symptom burden, high 
healthcare utilisation and poor health-related quality of life (HRQOL) [15-18]. Though frailty 
is linked with worse HRQOL in the general older population, the relationship between frailty 
and HRQOL is less certain in those with CKD [19]. The Frailty Phenotype is an 
operationalised definition of the construct of frailty and has been well studied in CKD 
cohorts [1,2]. It is a composite measure that involves 5 distinct components, including 
assessments of unintentional weight loss, weakness, slowness, physical activity and 
exhaustion. The relative significance of these individual components on HRQOL in patients 
with CKD is not known. Understanding how frailty and its components affect HRQOL in 
those with CKD could assist in the development of targeted management strategies to 
improve outcomes for this vulnerable patient group. 
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The purpose of this study was to: (1) evaluate the relationship between frailty, categorised 
by the Frailty Phenotype, and HRQOL; and (2) assess the relative significance of individual 
components of the Frailty Phenotype on HRQOL in patients with CKD stage 4 and 5 (G4-5) 
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MATERIALS AND METHODS 
 
Study Design and Participant Selection 
 
This was a secondary analysis of data from the ‘Frailty Assessment in Chronic Kidney 
Disease’ study that evaluated the diagnostic accuracy of frailty screening methods in a 
cohort of patients with advanced CKD [20]. Participants were recruited from nephrology 
outpatient clinics and two Haemodialysis Units at Lancashire Teaching Hospitals NHS 
Foundation Trust between December 2016 and December 2017. Patients 18 years old with 
CKD G4-5D were eligible for participation in the study. Exclusion criteria included patients 
who had a lower limb amputation, metastatic carcinoma, unstable angina or who had a 
been diagnosed, in the preceding 3 months, with a myocardial infarction, transient 
ischaemic attack or stroke. Written informed consent was obtained for all participants. 
Ethical approval was obtained from the NHS Health Research Authority (IRAS ID 216379) 




Baseline Data: Baseline demographic and clinical characteristic data was collected from 
medical records and during participant interview and assessment. This data included age, 
height, weight, co-morbidities, medication history, smoking history, blood pressure, falls 
history and laboratory variables. 
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Charlson Comorbidity Index: A Charlson Comorbidity Index (CCI) score was calculated for all 
participants [21]. The CCI is a commonly used assessment of comorbidity that is predictive 
of outcomes in CKD populations [22-24]. 
 
Karnofsky Performance Status Scale: A Karnofsky Performance Status Scale assessment, 
providing a measure of perceived performance that has been well-studied in CKD cohorts, 
was performed on all participants by a clinician [25,26]. 
 
Mini-Mental State Examination: The Mini-Mental State Examination (MMSE), a widely-used 
screening tool for cognitive impairment, was performed on all participants [27,28]. A cut-off 
27 has a higher sensitivity for identifying cognitive impairment in symptomatic populations 
than the conventional cut-off of <24 [27].   
 
Seniors in the Community: Risk Evaluation for Eating and Nutrition Index: All participants 
completed the Seniors in the Community: Risk Evaluation for Eating and Nutrition Index 
(SCREEN I), which is a validated nutritional risk screening tool for community-dwelling older 
adults [29,30]. A score 50 has been suggested to identify individuals at nutritional risk [30]. 
 
Frailty Assessment: Frailty was assessed using the Frailty Phenotype, which included 
assessments of unintentional weight loss, weakness (hand grip strength), slowness (walking 
speed), physical activity and self-perceived exhaustion. Frailty was diagnosed if 3 or more 
Frailty Phenotype components were present [1]: 
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1. The unintentional weight loss component was defined as a loss of 10 pounds or 5% 
body weight over the preceding 12 months [1]. 
 
2. Hand grip strength (Takei 5101 GRIP-D dynamometer, Takei Scientific Inst. Co. Ltd., 
Niigata, Japan) was assessed in the seated position with the elbow positioned at 90 
degrees, supported by the arm of a chair, and the dynamometer supported by the 
assessor [31]. Both arms were examined with the highest score from three efforts from 
each side being used for analysis. The body mass index and gender stratified hand grip 
strength cut-offs proposed by the Fried Frailty Phenotype were used to describe 
weakness [1]. 
 
3. Walking speed was assessed by asking participants to walk 15 feet (4.57m) at their 
normal walking pace on two occasions. Participants were advised to use their walking 
aid, if they normally used one. Infrared timing gates (Brower Timing System 2012, 
Brower Timing Systems, Draper, UT, USA) were used to record walking time. The fastest 
of two trials was used for analysis. Participants physically unable to complete the 
assessment were assigned the slowest time from within the cohort. The height and 
gender stratified walking speed cut-offs suggested by the Fried Frailty Phenotype were 
used to describe slowness [1]. 
 
4. Physical activity was assessed using a modified version of the Minnesota Leisure Time 
Questionnaire [32]. Low physical activity was defined as <383 kcals per week for men 
and <270 kcals per week for women [1].  
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5. Participants were read two statements from the Center for Epidemiological Studies 
Depression Scale to assess self-perceived exhaustion: (1) I felt that everything I did was 
an effort. (2) I could not get going [33]. Participants were then asked, ‘How often did you 
feel this?’ and provided the following scale: 0 = rarely or none of the time, 1 = some of 
the time, 2 = moderate amount of the time, 3 = most of the time. Self-perceived 
exhaustion was described if an answer 2 was given for either statement [1]. 
 
Health-Related Quality of Life: HRQOL was assessed using the RAND 36-Item Health Survey 
Version 1.0 (SF-36), which is validated in general and CKD populations [34-38]. The SF-36 
consists of 36 questions and assesses 8 domains of HRQOL: physical functioning, role 
limitations due to physical problems, role limitations due to emotional problems, emotional 
well-being, social functioning, energy/fatigue, pain and general health perceptions [34]. The 
answers to designated questions are transformed to create scores for HRQOL domains. The 
domain scores range from 0 to 100, with lower scores indicating worse HRQOL [34,35]. The 
SF-36 also asks ‘Compared to one year ago, how would you rate your health in 
general now?’. Participants answer on a 1-5 scale, with 1 being ‘much better now than one 




As a secondary analysis, no prospective sample size calculation was performed for the 
outcomes reported. Descriptive statistics were used to summarise demographic and clinical 
characteristic data. Pearson’s (for continuous data) or Spearman’s Correlation (for ordinal 
data) was used to assess the correlation between SF-36 domain scores and age and the 
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Frailty Phenotype and CCI scores. Multiple linear regression was used to assess the 
magnitude of association between frailty and SF-36 domain scores, adjusting for age, 
gender, dialysis-dependence and CCI scores, as well as, the magnitude of the association 
between Frailty Phenotype components and SF-36 domain scores. A p value <0.05 was 
considered statistically significant. All statistical analyses were performed on IBM SPSS 
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RESULTS 
 
Ninety participants completed the Frailty Phenotype assessment. Table 1 demonstrates the 
demographics and clinical characteristics of the overall cohort and of non-frail and frail 
participants. Nineteen (21%) participants were categorised as frail. Figure 1 illustrates the 
prevalence of Frailty Phenotype components. 
 
Participant Characteristics and HRQOL 
 
Mean SF-36 scores divided by frailty status, Frailty Phenotype components, age </65 years, 
gender and dialysis-dependence are shown in Table 2. Frail participants had significantly 
lower mean SF-36 scores in the following domains: physical functioning, role limitations due 
to physical health, energy/fatigue, social functioning and pain. Participants categorised as 
weak or slow also had significantly lower scores in these SF-36 domains. In addition to these 
domains, participants with low physical activity had significantly lower scores in the role 
limitations due to emotional problems domain. Those categorised as suffering from 
exhaustion had significantly lower scores across all SF-36 domains, whereas there was no 
significant difference in the mean SF-36 domain scores for participants who reached the 
unintentional weight loss threshold. Only participants categorised as weak had significantly 
higher (worse) median scores for the question regarding health change. 
 
Participants <65 years old had significantly lower SF-36 scores in the following domains: role 
limitations due to emotional problems, energy/fatigue and general health. Female 
participants had significantly lower scores in the physical functioning and energy/fatigue SF-
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36 domains. Participants receiving dialysis only had significantly lower scores in the physical 
functioning SF-36 domain.  
 
Correlation Between HRQOL and Frailty, Age and Comorbidity 
 
Table 3 demonstrates the correlation between SF-36 domains and Frailty Phenotype Score, 
age and CCI score. There was a significant negative correlation between all domain scores of 
the SF-36, except the general health domain, and Frailty Phenotype score. The correlation 
coefficients indicated a strong association between the physical functioning and 
energy/fatigue domain scores and the Frailty Phenotype score. There was a moderate 
association between the social functioning and pain domain scores and the Frailty 
Phenotype score. There was a significant positive correlation, though the coefficients 
revealed a weak association, between age and the following domain scores: role limitations 
due to emotional problems, emotional well-being, social functioning and general health. 
There was a significant negative correlation between CCI score and the SF-36 pain domain 
score; again, this coefficient only suggested a weak association.  
 
Influence of Frailty on HRQOL 
 
Regression analyses assessing the magnitude of the association between frailty and SF-36 
domains are presented in Table 4. Frailty, when adjusted for age, gender, dialysis-
dependence and CCI score, had a significant effect on the following SF-36 domains: physical 
functioning, role limitations due to emotional problems, energy/fatigue, social functioning, 
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and pain. Regression modelling best explained the variation in the physical functioning 
domain score, with frailty leading to a 26-point lower score. 
 
Regression analyses assessing the magnitude of the association between Frailty Phenotype 
components and SF-36 domains are displayed in Table 5. Self-perceived exhaustion was the 
only Frailty Phenotype component that had a significant effect on scores across all SF-36 
domains. Unintentional weight loss did not have a significant effect on any of the SF-36 
domain scores. Low physical activity had significant effects on physical functioning, role 
limitations due to emotional problems, energy/fatigue and social functioning domains. 
Weakness had a significant effect on the physical functioning and general health domains, 
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DISCUSSION 
 
To our knowledge, this is the first study that explores the relationship between frailty, as 
categorised by the original Frailty Phenotype, and HRQOL in those with CKD G4-5 and CKD 
G5D. Furthermore, it is the first study that assesses the relative significance of individual 
Frailty Phenotype components on HRQOL in this distinct patient group. Studies by Mansur 
et al and Lee et al have demonstrated that frailty is associated with worse HRQOL in those 
with CKD [13,14]. However, both studies used a modified version of Frailty Phenotype to 
categorise frailty, replacing objective measures of grip strength and walking speed with a 
self-report assessment of physical function [13,14]. Such an approach has been shown to 
substantially over-estimate the prevalence of frailty [39]. Furthermore, the self-report 
assessment used was the physical functioning domain of the SF-36, which was also used 
within the assessment of HRQOL [13,14,35] Additionally, the ‘vitality domain’ of the SF-36 
was used to determine the exhaustion component of their modified Frailty Phenotype 
[13,14,35]. Therefore, it is difficult to interpret the findings given the overlap of the frailty 
and HRQOL assessments. Iyasere et al demonstrated that frailty was associated with worse 
HRQOL, symptom burden and depression scores in those with dialysis-dependent CKD [40]. 
Their study used the Clinical Frailty Scale that relies upon a healthcare professional’s 
assessment of frailty based upon descriptors of levels of frailty [41]. Though not as well-
studied as the Frailty Phenotype in CKD populations, the Clinical Frailty Scale has been 
shown to be an accurate screening tool for frailty (identified by the Frailty Phenotype) [20] 
and predictive of mortality in patients with CKD [24,42]. 
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Our study confirms that frailty is significantly associated with worse HRQOL in patients with 
CKD G4-5D. Frailty Phenotype scores correlated with 7 of the 8 domains of the SF-36. Frail 
participants had significantly lower mean scores across 5 of the 8 domains, specifically 
physical functioning, role limitations due to physical health, energy/fatigue, social 
functioning and pain domains. When adjusted for age, gender, dialysis-dependence and CCI, 
frailty was independently associated with at least a 20-point lower score in physical 
functioning, role limitations due to emotional problems, energy/fatigue, social functioning 
and pain SF-36 domains. Notably, when adjusting for frailty, burden of comorbidity had no 
effect on SF-36 scores. Older age was not associated with worse HRQOL, in fact older age 
was associated with a modest improvement in several SF-36 domains. This relationship has 
been reported previously and is perhaps due to changes in emotional regulation with age 
[43-45]. Female participants had worse HRQOL, specifically in physical functioning and 
energy/fatigue domains, a finding that has been reported elsewhere in the literature 
[43,46,47]. However, there was no significant effect noted within the regression model that 
included frailty. Frailty was an independent predictor of poor HRQOL in this advanced CKD 
cohort, highlighting the importance of the construct of frailty, over and above more 
traditional predictors of HRQOL [43], and emphasising the importance of frailty screening in 
advanced CKD populations. 
 
Participants categorised as exhausted, regardless of whether they were classified as frail 
overall, had lower mean scores across all SF-36 domains. Depending on the SF-36 domain, 
the exhaustion Frailty Phenotype component was associated with 10- to 46-point lower 
score. Studies within the general older population have also found that this domain had the 
greatest effect on HRQOL [47,48]. Exhaustion, also known as fatigue, is a commonly 
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reported and especially problematic symptom in patients with advanced CKD, particularly 
for those receiving dialysis [49-51]. Fatigue is not only associated with worse HRQOL, but 
also survival in advanced CKD, with the HEMO study demonstrating that an increase of 10-
points in ‘vitality score’ was associated with a 10% increase in mean survival [52,53]. 
Accordingly, addressing the causes of fatigue may be associated with improved HRQOL and 
survival in non-frail and frail patients alike. This is a challenging undertaking, as fatigue is a 
complex multi-dimensional and multi-factorial issue [50]. Appropriate management of renal 
anaemia, adequate nutrition and prompt management of concurrent medical problems is 
essential [50]. However, there is also an association between fatigue and psychological 
distress, therefore therapies that address mood and anxiety issues, may also be associated 
with an improvement in fatigue symptoms [50,54]. Sleep disorders are common in those 
with advanced CKD [55]. Cognitive behavioural therapy leads to improved sleep quality and 
reduced fatigue, thus it may be a useful therapy for frail patients with CKD [56]. 
Furthermore, low physical activity levels are associated with increased levels of fatigue [57]. 
Exercise improves fatigue in the general population and has been shown to improve HRQOL 
and fatigue in those with advanced CKD [58-60]. Evidence to-date suggests that exercise 
training can improve physical function and HRQOL in frail older adults [61-63]. However, 
studies have not targeted pre-frail and frail patients with CKD, a group of patients who are 
typically poorly represented in interventional studies [64,65]. Further evidence is needed on 
the feasibility of a rehabilitation programme for frail patients with advanced CKD. 
Ultimately, management strategies likely need to be multimodal and multidisciplinary, 
including nutritional, psychological and rehabilitation components [50,66]. Additional 
evaluation of the relationship between fatigue and HRQOL in frail advanced CKD 
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populations is needed, particularly to assess the relative contributions of physical capacity 
and psychological well-being.  
 
There are acknowledged limitations of this study. Firstly, the cross-sectional study design 
does not allow for conclusions to be made on causation. Longitudinal studies are required to 
assess for a causal relationship between frailty and HRQOL. Secondly, further investigation 
within more culturally diverse populations is needed given that participants within this 
study were recruited from a single-centre with a predominantly White British population. 
Finally, this is a secondary analysis of a study that was powered to assess the diagnostic 
accuracy of frailty screening methods in advanced chronic kidney disease, therefore the 




Frailty is independently associated with worse HRQOL in patients with CKD G4-5D. 
Exhaustion, or fatigue, is the most significant Frailty Phenotype component contributing to 
worse HRQOL in those with advanced CKD. Efforts should be made to identify frail patients 
with CKD so that management strategies can be offered that aim to improve morbidity, 
mortality and patient-reported outcomes, including HRQOL and fatigue. Additional study is 
needed to determine the most significant contributors to fatigue in frail patients with 
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TABLES 







Age (years) 69 (13) 68 (13) 73 (11) 
Female, n (%) 45 (50) 30 (42) 15 (79) 
BMI (kg/m2) 29 (6) 29 (6) 28 (6) 
CKD Stage 
- CKD G4-5, n (%) 










CCI, median (IQR) 3 (2) 3 (2) 4 (4) 
Diabetes Mellitus, n (%) 24 (27) 16 (23) 8 (42) 
Karnofsky Score, median (IQR) 70 (30) 80 (20) 60 (20) 
Medications 9 (4) 8 (3) 11 (5) 
Current or ex-smoker, n (%) 49 (54) 40 (56) 9 (47) 
MMSE Score 27*, n (%) 18 (20) 13 (19) 5 (29) 
Fall within last 6 months, n (%) 16 (18) 11 (15) 5 (26) 
SCREEN I Score 50, n (%) 70 (78) 53 (75) 17 (89) 













- Haemoglobin (g/L) 
- White Cell Count (x 109/L) 
- CRP** (mg/L), median (IQR) 
- Albumin (g/L) 




















Data presented as mean ( SD) unless otherwise specified. *MMSE data was available for 87 
participants. **CRP data was available for 64 participants. BMI, Body Mass Index. CCI, 
Charlson Comorbidity Index. MMSE, Mini-Mental State Examination. SCREEN I, Seniors in 
the Community: Risk Evaluation for Eating and Nutrition Index. CRP, C-Reactive Protein.  
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Table 2. SF-36 Scores divided by Frailty Status, Frailty Criteria Component, Age (< or 65 years), Gender and Dialysis-Dependence. 
 







Due to Physical 
Health 
Role Limitations 





























































































































































































-  <65 years 



























































- CKD G4-5 




























Frailty and Quality of Life in CKD 
 
   31 










Due to Physical 
Health 
Role Limitations 










(0.77 to -0.50) 
-0.38* 
(-0.55 to -0.20) 
-0.35** 
(-0.54 to -0.15) 
-0.65* 
(-0.76 to -0.51) 
-0.27** 
(-0.47 to -0.06) 
-0.52* 
(-0.68 to -0.33) 
-0.53* 
(-0.68 to -0.36) 
-0.11 
(-0.31 to 0.11) 
Age, r -0.05 
(-0.24 to 0.15) 
0.01 
(-0.20 to 0.22) 
0.29** 
(0.08 to 0.48) 
0.17 
(-0.06 to 0.39) 
0.23*** 
(0.01 to 0.42) 
0.25*** 
(0.02 to 0.46) 
0.08 
(-0.14 to 0.30) 
0.22*** 
(0.03 to 0.41) 
CCI Score, rho -0.14 
(-0.34 to 0.08) 
-0.18 
(-0.38 to 0.02) 
0.06 
(-0.16 to 0.27) 
-0.09 
(-0.30 to 0.13) 
0.07 
(-0.14 to 0.28) 
-0.09 
(-0.31 to 0.13) 
-0.24*** 
(-0.43 to -0.04) 
-0.01 
(-0.23 to 0.21) 
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Table 4. Regression Analyses Assessing the Influence of Frailty, Age, Gender, Dialysis-
Dependence and Comorbidity on SF-36 Domains. 
















-25.75 (-41.19 to -10.32) 
-0.05 (-0.51 to 0.41) 
-10.01 (-22.06 to 2.04) 
-17.49 (-30.29 to -4.69) 

















Role Limitations Due to Physical Health 








Role Limitations Due to Emotional Problems 










-28.74 (-52.24 to -5.23) 
1.05 (0.35 to 1.75) 
9.59 (-8.75 to 27.94) 
0.22 (-19.26 to 19.71) 




























-20.28 (-32.33 to -8.22) 
0.46 (0.10 to 0.82) 
-6.90 (-16.31 to 2.51) 
2.35 (-7.64 to 12.34) 



























Social Functioning  










-23.41 (-40.07 to -6.74) 
0.75 (0.25 to 1.24) 
-5.31 (-18.32 to 7.70) 
-0.36 (-14.17 to 13.46) 




























-28.08 (-43.33 to -12.83) 
0.40 (-0.06 to 0.85) 
-2.02 (-13.93 to 9.88) 
-0.16 (-12.81 to 12.48) 



























Adj. R2, Adjusted R2; CCI, Charlson Comorbidity Index. 
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Table 5. Regression Analyses Assessing the Influence of Frailty Phenotype Components on 
SF-36 Domains. 





Physical Functioning  
Adj. R2 = 0.40, p <0.001 
 
- Weight Loss Frail 
- Weakness Frail 
- Slowness Frail 
- Physical Activity Frail 




-3.55 (-24.00 to 16.90) 
-11.89 (-23.41 to -0.37) 
-12.63 (-28.04 to 2.79) 
-11.76 (-23.11 to -0.40) 

















Role Limitations Due to Physical Health  
Adj. R2 = 0.13, p = 0.01 
 
- Weight Loss Frail 
- Weakness Frail 
- Slowness Frail 
- Physical Activity Frail 




0.17 (-32.93 to 33.28) 
-4.82 (-23.47 to 13.83) 
-4.07 (-29.03 to 20.89) 
-10.38 (-28.76 to 8.01) 

















Role Limitations Due to Emotional Problems 
Adj. R2 = 0.26, p <0.001 
 
- Weight Loss Frail 
- Weakness Frail 
- Slowness Frail 
- Physical Activity Frail 




-0.26 (-31.53 to 31.01) 
5.26 (-12.35 to 22.87) 
22.88 (-0.69 to 46.45) 
-21.00 (-38.36 to -3.64) 


















Adj. R2 = 0.54, p <0.001 
 
- Weight Loss Frail 
- Weakness Frail 
- Slowness Frail 
- Physical Activity Frail 




-0.07 (-13.19 to 13.06) 
3.96 (-3.43 to 11.36) 
-4.34 (-14.23 to 5.55) 
-15.56 (-22.85 to -8.27) 


















Adj. R2 = 0.12, p = 0.01 
 
- Weight Loss Frail 
- Weakness Frail 
- Slowness Frail 
- Physical Activity Frail 




-6.29 (-22.68 to 10.10) 
7.21 (-2.03 to 16.44) 
0.07 (-12.29 to 12.43) 
-4.51 (-13.61 to 4.59) 
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Table 5. Continued. 
 






Adj. R2 = 0.24, p <0.001 
 
- Weight Loss Frail 
- Weakness Frail 
- Slowness Frail 
- Physical Activity Frail 




10.02 (-12.89 to 32.93) 
-1.35 (-14.26 to 11.56) 
-0.87 (-18.14 to 16.40) 
-16.89 (-29.61 to -4.16) 


















Adj. R2 = 0.44, p <0.001 
 
- Weight Loss Frail 
- Weakness Frail 
- Slowness Frail 
- Physical Activity Frail 




10.71 (-7.69 to 29.10) 
4.64 (-5.73 to 15.00) 
-23.57 (-37.44 to -9.71) 
-3.12 (-13.33 to 7.10) 


















Adj. R2 = 0.08, p = 0.04 
 
- Weight Loss Frail 
- Weakness Frail 
- Slowness Frail 
- Physical Activity Frail 




11.17 (-3.82 to 26.16) 
8.67 (0.23 to 17.12) 
-3.73 (-15.03 to 7.57) 
-4.62 (-12.94 to 3.70) 
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FIGURE LEGEND 
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